Join us for a free breast cancer symposium.
Hear about our research advances in new treatments, drug resistance and metastasis, as well as new clinical trials.
Hosted by Associate Professors, Elgene Lim and Alex Swarbrick, the symposium will include an international keynote speaker, Garvan researchers and oncologists and guest speakers
Date: Friday, 13 March 2020
Time: 2-4pm, followed by light refreshments
Location: Garvan Institute of Medical Research
Cost: Free of charge – registration is essential
Meet our guest speakers
A/Prof Elgene Lim,
is a medical oncologist and researcher with a focus on breast cancer...
research and treatment, and a clinical academic at St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney. A/Prof Elgene Lim's research findings the identification of the culprit cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome.He completed my medical and oncology training, and doctoral research in Melbourne. Findings from his PhD research under the mentorship of Geoffrey Lindeman and Jane Visvader at the Walter and Eliza Hall Institute, had a major impact on the identification of the culprit cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome. He furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School under the mentorship of Eric Winer and Myles Brown, both internationally acclaimed leaders in breast cancer research and clinical trials, through fellowships from the Fulbright Foundation, National Health and Medical Research Council of Australia, and Royal Australasian College of Physicians.
A/Prof Alex Swarwick,
is the Lab Head of the Tumour Progression Lab at Garvan Insitute
A/Prof Alex Swarwick established the Tumour Progression Laboratory in the Garvan Institute and in 2012 was appointed co-Head of the Breast Translational Oncology Program in the Kinghorn Cancer Centre. Alex is an Associate Professor at UNSW and an NHMRC Senior Research Fellow. A/Prof Swarick is also the convenor of the Lorne Cancer Conference, Australia's pre-eminent multi-disciplinary cancer research conference & the Australian Translational Breast & Prostate Cancer Symposium
Dr Sarat Chandarlapaty, MD, PhD, is a medical oncologist and a Lab Head at...
Memorial Sloan Kettering Cancer Center in New York. A major focus of his work has been to characterize the significance of alterations present in metastatic tumours that have progressed following targeted therapies such as antiestrogens or CDK4/6 inhibitors.
Dr Sarat Chandarlapaty earned his medical degree at the Wake Forest School of Medicine and his PhD at the University of North Carolina. Following this he completed his residency at New York Presbyterian Hospital, and his fellowship at Memorial Sloan Kettering Cancer Center. Another major focus of his work is developing models of resistant cancer for testing newer therapeutic strategies. He has been a Breast Cancer Research Foundation/Estee Lauder funded researcher since 2015.
Dr Liz Caldon, In her PhD studies, Dr Caldon investigated the interaction between...
hormone signalling and proliferative control of breast cancer cells. The primary goal of her research at Garvan it to understand the evolution of hormone therapy resistance in breast cancer, which is a major cause of breast cancer-related death.
Dr Liz Caldon leads the Replication and Genome Stability research group at Garvan. The Replication and Genome Stability group works towards understanding the way that cancer cells evolve due to the selective pressure of therapeutic drugs and cancer driver genes called oncogenes.
Celebrity guest speaker
is a much loved Australian designer, her designs have captured the imagination of the world with its vibrant and bespoke bohemian lifestyle offering.
In 2018, just months after giving birth to her daughter, Camilla was diagnosed with a rare form of breast cancer. Camilla received 6 months of intense chemotherapy, double mastectomy and reconstruction. Camilla was treated by Oncologist, Dr. Elgene Lim at the Kinghorn Cancer Centre.